Geneva, June 16, 2025, Genii Longevity Conference
At the Genii Longevity Conference: Innovation Through Investments, held in Geneva next to the United Nations, Unlimited Bio COO Vladimir Leshko presented the company’s Combination Gene Therapy platform, framing it as the new gold standard for tackling aging.
Key highlights from his talk and the event:
“Combination approaches are not the future — they are the present. To reprogram aging, we must act across pathways simultaneously, and do it now,” Vladimir Leshko said.
The Geneva event reinforced Unlimited Bio’s role as one of the most dynamic players in preventive gene therapy, bridging science, biotech startups, and global policy.
At the Genii Longevity Conference: Innovation Through Investments, held in Geneva next to the United Nations, Unlimited Bio COO Vladimir Leshko presented the company’s Combination Gene Therapy platform, framing it as the new gold standard for tackling aging.
Key highlights from his talk and the event:
- Combination Strategy. Unlimited Bio builds synergistic cocktails (VEGF, Follistatin, Klotho, BDNF) to reprogram multiple aging pathways simultaneously.
- Regulatory Paradox. Leshko noted Switzerland allows assisted suicide more easily than experimental right-to-try therapies — underlining the need for regulatory reform.
- Global Expansion. The Geneva College of Longevity Science announced operations in China, expanding representation in the field.
- Funding Innovation. The Longevity Science Foundation, led by Joshua Herring, was highlighted as a new force funding anti-aging research.
- Startup Ecosystem. Standout projects included SYDRA’s AI screening of 6M molecules, ateka|tx’s BDNF receptor activators, and diagnostics from Quant Biomarkers. More unconventional ideas, like MemoryGarden’s VR therapy for dementia, sparked lively debate.
“Combination approaches are not the future — they are the present. To reprogram aging, we must act across pathways simultaneously, and do it now,” Vladimir Leshko said.
The Geneva event reinforced Unlimited Bio’s role as one of the most dynamic players in preventive gene therapy, bridging science, biotech startups, and global policy.